Pliant Therapeutics Inc banner

Intrinsic Value

The intrinsic value of Pliant Therapeutics Inc (9PT) under the Base Case is 2.5677 EUR per share. Compared with the current market price of 0.6435 EUR, the stock appears Undervalued by 75% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

9PT Intrinsic Value
€2.5677
Undervaluation 75%
Intrinsic Value
Price €0.6435
Alert me when 9PT is below its intrinsic value
Today €2.0542 · Already reached, the price is 68.7% below it

9PT is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alternatives to 9PT

Fundamental Analysis

What Pliant Therapeutics Does

Pharmaceuticals Health Care

Pliant Therapeutics is a biotechnology company that develops drug candidates for fibrotic diseases, where the body makes too much scar tissue in organs such as the lungs. Its main focus has been on medicines that block integrins, proteins that help drive the scarring process. The company is still in the drug-development stage, so it does not sell a commercial medicine yet.

Headquarters
United States of America US
Employees
49
IPO date
Jun 3, 2020
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Pliant Therapeutics insiders are selling less than usual

Insider trading · Last trade on Jan 20, 2026

Sold $163.6k 4 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Continue 9PT Research

Decided on Pliant Therapeutics? Get an email when 9PT reaches the price you’d buy at. Free with an account.

Other Pliant Therapeutics listings

What is the Intrinsic Value of one 9PT stock?

The intrinsic value for Pliant Therapeutics Inc (9PT) under the Base Case is 2.5677 EUR.

Is 9PT stock undervalued or overvalued?

Compared with the current market price of 0.6435 EUR, the stock appears Undervalued by 75% .

How reliable are our estimates? See how past valuations played out
Back to Top